Literature DB >> 5270204

The production of neutralizing activity in serum and nasal secretion following immunization with influenza B virus.

J C Downie, C H Stuart-Harris.   

Abstract

Trials were made in volunteers in 1967 and 1968 of various virus vaccines against influenza virus B. Sera and serially collected nasal washings before and after immunization were tested respectively for haemagglutination-inhibiting and tissue culture virus-neutralizing antibodies to the same strain of influenza B/Eng/65 virus as that used in the vaccines. Infection, as determined by recovery of virus and serological changes following intranasal instillation of attenuated live virus, was accompanied by the subsequent appearance of neutralizing antibodies in nasal secretion. Inactivated vaccine subcutaneously did not evoke nasal antibody formation in 1967 but did so in 1968.In 1968 intranasal challenge of the volunteers with the attenuated virus 1 month after immunization demonstrated a correlation of susceptibility or resistance to infection with nasal and serum antibodies. Resistance appeared to depend either on a high level of serum antibodies or nasal antibodies, or both.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5270204      PMCID: PMC2130804          DOI: 10.1017/s0022172400028709

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  22 in total

1.  Technique of complementfixation test applicable to the diagnosis of virus diseases.

Authors:  C M BRADSTREET; C E TAYLOR
Journal:  Mon Bull Minist Health Public Health Lab Serv       Date:  1962-05

2.  Inactivated influenza virus vaccines. Past, present, and future.

Authors:  F M DAVENPORT
Journal:  Am Rev Respir Dis       Date:  1961-02

3.  PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

Authors:  J E Salk; H E Pearson; P N Brown; T Francis
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

4.  THE INACTIVATION OF EPIDEMIC INFLUENZA VIRUS BY NASAL SECRETIONS OF HUMAN INDIVIDUALS.

Authors:  T Francis
Journal:  Science       Date:  1940-02-23       Impact factor: 47.728

5.  Neutralizing and hemagglutination-inhibiting activity of nasal secretions following experimental human infection with A2 influenza virus.

Authors:  R H Alford; R D Rossen; W T Butler; J A Kasel
Journal:  J Immunol       Date:  1967-04       Impact factor: 5.422

6.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

7.  The role of nasal secretion and serum antibody in the rhinovirus common cold.

Authors:  T R Cate; R D Rossen; R G Douglas; W T Butler; R B Couch
Journal:  Am J Epidemiol       Date:  1966-09       Impact factor: 4.897

8.  Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine.

Authors:  J A Kasel; E B Hume; R V Fulk; Y Togo; M Huber; R B Hornick
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

9.  Investigetion into the attenuation of influenza viruses by serial passage.

Authors:  A S Beare; M L Bynoe; D A Tyrrell
Journal:  Br Med J       Date:  1968-11-23

10.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

View more
  13 in total

1.  A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.

Authors:  C W Potter; R Jennings; C McLaren; D Edey; C H Stuart-Harris; M Brady
Journal:  J Hyg (Lond)       Date:  1975-12

2.  Clinical trial with "R-75" strain live, attenuated, serum inhibitor-resistant intranasal influenza B vaccine.

Authors:  M J Spencer; J D Cherry; K R Powell
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

3.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

4.  Antibody response to inactivated influenza vaccine given by different routes in patients with chronic bronchopulmonary disease.

Authors:  S L Shore; C W Potter; C H Stuart-Harris
Journal:  Thorax       Date:  1973-11       Impact factor: 9.139

5.  Neuraminidase and resistance to vaccination with live influenza A2 Hong Kong vaccines.

Authors:  A N Slepushkin; G C Schild; A S Beare; S Chinn; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1971-12

6.  Immunity to influenza in ferrets. X. Intranasal immunization of ferrets with inactivated influenza A virus vaccines.

Authors:  C McLaren; C W Potter; R Jennings
Journal:  Infect Immun       Date:  1974-06       Impact factor: 3.441

7.  Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine.

Authors:  F L Ruben; C W Potter; C H Stuart-Harris
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

8.  A contribution of cellular immunity to protection against influenza in man.

Authors:  R Jennings; R J Fenton; M G McEntegart; C W Potter
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

9.  The sequential appearance of antibody and immunoglobins in nasal secretion after immunization of volunteers with live and inactivated influenza B virus vaccines.

Authors:  J C Downie
Journal:  J Hyg (Lond)       Date:  1973-09

10.  Regional T- and B-cell responses in influenza-infected ferrets.

Authors:  C McLaren; G M Butchko
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.